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ABSTRACT
It was suggested that intravenous thrombolysis (IT) leads to larger extent recanalization 
in cardioembolic stroke. In this work we assess if this has beneficial clinical traduction. 
Method: We evaluated 177 patients undergoing IT, which were categorized into 
cardioembolic (CE) and non-cardioembolic (NCE). National Institutes of Health Stroke Scale 
(NIHSS) and modified Rankin scale were compared. Results: The mean age was 67.4±12.01 
and 53.8% were male. The mean NIHSS was: 14 (admission), 9 (24 h) and 6 (discharge), 
similar in subgroups. The difference between NIHSS at admission and 24 hours was 
4.17±4.92 (CE: 4.08±4.71; NCE: 4.27±5.17, p=0.900) and at admission and discharge there 
was an average difference of 6.74±5.58 (CE: 6.97±5.68; NCE: 6.49±5.49, p=0.622). The mRS 
at discharge and 3 months was not significantly different by subtype, although individuals 
whose event was NCE are more independent at 3 months. Conclusion: Ours findings 
argue against a specific paper of IT in CE. It can result from heterogeneity of NCE group.
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A trombólise endovenosa é mais eficaz nos acidentes vasculares cerebrais isquêmicos 
cardioembólicos do que nos não cardioembólicos?
RESUMO
Alguns estudos sugerem que a trombólise endovenosa (TE) conduz a melhor recanalização 
nos acidentes vasculares cerebrais isquêmicos (AVCI) cardioembólicos. Neste trabalho 
questionamos se isto terá tradução em benefício clínico. Método: Avaliamos 177 
doentes submetidos a TE, os quais foram categorizados como cardioembólicos (CE) e 
não cardioembólicos (NCE). Compararam-se a National Institutes of Health Stroke Scale 
(NIHSS) e escala de Rankin modificada. Resultados: A idade média foi 67,4±12,01 e 
53,8% eram homens. NIHSS média foi: 14 (admissão), 9 (24 h), 6 (alta), semelhante nos 
subgrupos. A diferença entre NIHSS à admissão e 24 h foi de 4,17±4,92 (CE: 4,08±4,71; 
NCE: 4,27±5,17, p=0,900) e entre a admissão e a alta de 6,74±5,58 (CE: 6,97±5,68; 
NCE: 6,49±5,49, p=0,622). A classificação na mRS não foi significativamente diferente 
nos subgrupos (alta e 3 meses), mas os doentes com eventos NCE estavam mais 
independentes aos 3 meses. Conclusão: Os nossos resultados não documentam um 
papel específico da TE nos CE, o que pode resultar da heterogeneidade do grupo NCE.
Palavras-Chave: cardioembolismo, acidente vascular cerebral, trombólise.
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Stroke incidence in rural and urban 
Northern Portugal is high compared to 
that reported in other Western Europe 
regions1 As ischemic stroke results from 
artery occlusion, repermeabilization is the 
main therapeutic target, and early recana-
lization seems to increase clinical recovery 
and to diminish long-term disability2-5. 
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Intravenous thrombolysis in acute ischemic stroke is 
effective in improving functional measures and neuro-
logic outcome in a defined subgroup of stroke patients 
with moderate to severe neurologic deficit and without 
extense infarct on initial CT scan6. Although intravenous 
thrombolysis with alteplase (rt-PA) is the most effective 
treatment for acute ischemic stroke, the benefit can vary 
according to size, composition and origin of thrombus7. 
Old clots rich in platelets, well organized and formed in 
flow conditions are more resistant than fresh clots, rich 
in fibrin and blood cells, and formed under conditions of 
stasis8. Previous evidence suggests that rt-PA produces 
earlier, faster and larger recanalization in middle cerebral 
artery cardioembolic strokes as compared with other 
subtypes7. In this study we aim to assess if this fact has 
any clinical translation, that is, if patients with cardioem-
bolic stroke have an additional clinical benefit from rt-PA. 
METHOD
We included all patients treated with rt-PA for isch-
emic stroke at our Hospital, between February 9, 2007 
and May 18, 2010, in a total of 177 individuals. Twenty 
one patients were excluded from analysis because they 
did not complete the etiological investigation (14 were 
transferred to other hospitals and seven died before this).
Data related to gender, age, etiology according to 
TOAST criteria9, National Institutes of Health Stroke 
Scale (NIHSS) at admission, 24 hours and discharge 
and modified Rankin scale (mRS) at discharge and three 
months, were prospectively collected.
For the etiologic classification, we carried out electro-
cardiogram, transthoracic and/or transesophageal ecoca-
rdiogram, cervical Doppler and Holter (in selected cases). 
Final classification was done by a stroke neurologist.
For statistical analysis, the population was divided in 
two groups cardioembolic (CE) and non-cardioembolic 
(NCE), and characterized regarding age, gender and vas-
cular risk factors. We compared NIHSS at admission, 
24h and discharge. NIHSS difference between admission 
and 24 hours, and admission NIHSS and discharge, were 
calculated. Rankin at discharge and at three months after 
thrombolysis was also compared between groups. 
Statistical analysis was performed with SPSS 18.0, 
using the Chi-square test (χ2), Mann-Whitney and t-
test for difference of means in independent samples, as 
appropriate.
RESULTS
During the study period, intravenous thrombolysis 
was performed in 177 subjects of which 81 were classi-
fied as cardioembolic (51.9%). Twenty-one individuals 
were excluded from analysis for not having completed 
the etiological investigation.
Patients mean age was 67.4±12:01 (CE: 69.3±11.65; 
NCE: 65.44±12.14; p=0.268). Eighty four individuals 
were males (53.8%); 41 (50.6%) in CE, 43 (57.3%) in NCE; 
p=0.401. Eighty six subjects were hypertensive (55.1%); 
46 (56.8%) in CE, 40 (53.3%) in NCE; p=0.664. Thirty-
one patients (19.9%) were diabetic, with a higher preva-
lence in the NCE group (22 subjects, 29.3%), the differ-
ence reaching statistical meaning (p=0.004).
The mean symptom-needle time was 139.9±42.50 
minutes (CE: 143.4±35.39; NCE: 136.3±48.94; p=0.203). 
The mean door-needle time was 52.6±16:56 minutes (CE: 
7.97±54.0; NCE: 51.2±14.95; p=0.611).
The mean NIHSS at admission, 24 hours, and at dis-
charge was not statistically different between CE and 
NCE (Table 1). NIHSS at admission and at 24 hours was 
subdivided, but still no significant differences were found 
(Table 2). 
The mean difference between NIHSS at admission 
and at 24 hours was 4.92±4:17 (CE: 4.08±4.71; NCE: 
4.27±5.17; p=0.900). The mean difference between 
NIHSS at admission and discharge was 6.74±5:58 (CE: 
6.97±5.68; NCE: 6.49±5.49; p=0.622) (Table 3).
Disability after stroke according to mRS at discharge 
was not significantly different by subtype (p=0.305). At 
3 months there were also no significant differences be-
tween groups (p=0.135). When comparing independent 
(mRS≤2) with dependent (mRS>2) patients, there was 
no significant differences at discharge (p=0.509), but 
the NCE group has more independent individuals at 3 
months (p=0.037) (Table 4).
DISCUSSION
Early recanalization seems to lead to lower infarct 
size and a better clinical outcome2,3,5. Moreover, early 
recovery after recanalization after rt-PA is sustained at 
three months in most patients4. So, in fact, early recana-
lization is a powerful independent predictor of functional 
independence at three months3. This is mostly because 
of faster and more complete clot breakup with low re-
sistance of the distal circulatory bed5. In the other hand, 
fewer patients achieve good long-term outcome without 
early recanalization4.
Table 1. Comparison of the mean NIHSS at admission, 24 hours 
and discharge.
Total CE NCE p
NIHSS
admission
14 (13.68) 15 (14.67) 13 (12.61) 0.272
NIHSS 
24 hours
9 (9.30) 11 (10.47) 8 (8.04) 0.737
NIHSS
discharge
6 (6.44) 7 (7.23) 6 (5.61) 0.149
CE: cardioembolic; NCE: non-cardioembolic.
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Table 2. Mean age, gender, hypertension (HT), diabetes mellitus (DM), NIHSS at admission, 24 hours, and discharge, by cardioembolic 
and non-cardioembolic subtypes.
All events
(n=156)
Cardioembolics 
(n=81; 51.9%)
Non-cardioembolics 
(n=75; 48.1%) p
Mean age (age±standard deviation) 67.4±12.01 69.3±11.65 65.44±12.14 0.268
Gender
   Men [n(%)] 84 (53.8) 41 (50.6) 43 (57.3) 0.401
HT [n(%)] 86 (55.1) 46 (56.8) 40 (53.3) 0.664
DM [n(%)] 31 (19.9) 9 (11.1) 22 (29.3) 0.004
NIHSS at admission [n(%)] 0.142
   0-5 6 (3.8) 3 (3.7) 3 (4.0)
   6-10 45 (28.8) 17 (21.0) 28 (37.3)
   11-15 42 (26.9) 22 (27.1) 20 (26.7)
   16-20 43 (27.6) 28 (27.1) 15 (20.0)
   >21 19 (12.2) 11 (13.6) 8 (16.7)
   Unknwon 1 (0.6) 0 (0.0) 1 (1.3)
NIHSS at 24hours [n(%)] 0.106
   0-5 56 (35.9) 24 (29.6) 32 (42.7)
   6-10 30 (19.2) 13 (16.0) 17 (22.7)
   11-15 29 (18.6) 19 (23.4) 10 (13.3)
   16-20 25 (16.0) 17 (21.0) 8 (10.7)
   >21 11 (7.1) 5 (6.2) 6 (8.0)
   Unknwon 5 (3.2) 3 (3.7) 2 (2.7)
NIHSS at discharge [n(%)] 0.424
   0-5 81 (51.9) 38 (46.9) 43 (57.3)
   6-10 24 (15.4) 12 (14.8) 12 (16.0)
   11-15 20 (12.8) 11 (13.6) 9 (12.0)
   16-20 17 (10.9) 11 (13.6) 6 (8.0)
   >21 2 (1.3) 2 (2.5) 0 (0.0)
   Unknwon 12 (7.7) 7 (8.6) 5 (6.7)
Rankin at discharge [n(%)] 0.305
   0 30 (19.2) 10 (12.3) 20 (26.7)
   1 22 (14.1) 13 (16.0) 9 (12.0)
   2 29 (18.6) 17 (21.0) 12 (16.0)
   3 27 (17.3) 12 (14.8) 15 (20.0)
   4 35 (22.4) 21 (26.0) 14 (18.7)
   5 3 (1.9) 2 (2.5) 1 (1.3)
   6 10 (6.4) 6 (7.4) 4 (5.3)
Rankin at three months [n(%)] 0.135
   0 27 (17.3) 14 (17.3) 13 (17.3)
   1 24 (15.4) 7 (8.6) 17 (22.7)
   2 25 (16.0) 13 (16.0) 12 (16.0)
   3 19 (12.2) 13 (16.0) 6 (8.0)
   4 15 (9.6) 10 (12.3) 5 (6.7)
   5 1 (0.6) 0 (0.0) 1 (1.3)
   6 17 (10.9) 10 (12.3) 7 (9.3)
   Unknwon 28 (17.9) 14 (17.3) 14 (18.7)
NIHSS: National Institutes of Health Stroke Scale.
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Molina et al., compared the time, speed and degree of 
rt-PA induced recanalization in patients with proximal 
middle cerebral artery occlusion of different subtypes7. In 
this study, the authors, using transcranial doppler, mon-
itored the recanalization during rt-PA infusion and at 
six hours, comparing large-vessel disease strokes, car-
dioembolic strokes and strokes of undetermined origin. 
One-hour recanalization was more frequent in patients 
with cardioembolic stroke compared with the other sub-
types. Rate of complete recanalization at six hours was 
also higher in cardioembolic stroke. Thus, it was dem-
onstrated that the pattern of rt-PA induced middle cere-
bral artery recanalization differs among stroke subtypes. 
The authors also concluded that sudden recanalization 
was associated with a higher degree of neurological im-
provement at 24 hours and at long-term compared with 
stepwise, slow, or absent recanalization7. 
Differential patterns of the speediness, degree and 
temporal profile of clot dissolution may reflect struc-
tural differences of the clots8. In this context, stroke sub-
types may represent a surrogate of clot composition and 
differences in the response to rt-PA in terms of recana-
lization. Cardioembolic stroke probably represents the 
stroke subtype with more uniform fibrin-rich clots, given 
the high binding affinity of rt-PA for fibrin. In contrast, 
in well organized and platelet-rich clots, penetration and 
distribution of rt-PA are limited. In the other hand, the 
presence of an extracranial internal carotid artery occlu-
sion might hamper the delivery of an adequate dose of 
rt-PA into the ipsilateral occlude middle cerebral artery7.
Hsia et al., achieved the relationship between final 
stroke subtype (after diagnostic evaluation has been 
completed) and response to thrombolytic therapy. They 
concluded that the efficacy of intravenous thrombolysis 
within the threee hours time window is similar between 
different stroke subtypes10.
In our study, no significant differences were found be-
tween NIHSS at admission, 24 hours and three months, 
by subgroups. However, in our population, patients 
with non-cardioembolic events are more independent 
for daily life activities at three months. In our study, we 
didn’t assess recanalization because transcranial doppler 
monitoring was not performed during thrombolysis, and 
stroke subtypes were not adjusted by stroke severity and 
location of arterial occlusion. Furthermore, in our study 
we compared cardioembolic with non-cardioembolic 
events, while in the study work up by Molina et al.7 it 
was compared cardioembolic events with events classi-
fied as “large vessels disease” and as “undetermined or-
igin”. Clots from cardioembolism are theoretically richer 
in fibrin and therefore more prone to thrombolytic fix-
ation, while occlusion in large vessels disease are mostly 
caused by very organized platelets rich clots, which are 
more difficult to dissolve. However, in our study, the 
non-cardioembolic group includes events whose occlu-
sion could have been caused by clots of intermediate fea-
tures, because this group can include other stroke eti-
ology beyond large vessel disease. 
Based on our results, we concluded that early neu-
rological recovery, at 24 hours and at discharge, mea-
sured by NIHSS and mRS was not significant different 
between stroke subtypes. Thus, we hypothesize that the 
pattern of rt-PA induced recanalization did not differ 
among cardioembolic and non cardioembolic strokes. 
Table 4. Comparison of modified Rankin scale at discharge and at three months.
All events
(n=156)
Cardioembolics 
(n=81; 51.9%)
Non-Cardioembolics 
(n=75; 48.1%) p
Rankin at discharge [n(%)]
   ≤2 81 (51.9) 40 (49.4) 41 (54.7) 0.509 
   >2 75 (48.1) 41 (50.6) 34 (45.3)
   Unknown 0 (0.0) 0 (0.0) 0 (0.0) 
Rankin three months [n(%)] 
   ≤2 76 (48.7) 34 (42.0) 42 (56.0) 0.037
   >2 52 (33.3) 33 (40.7) 19 (25.3)
   Unknown 28 (17.9) 14 (17.3) 14 (18.7) 
Table 3. Comparison of the differences between NIHSS at admission - 24 hours and at admission - discharge.
All events 
(n=156)
Cardioembolics 
(n=81; 51.9%)
Non-Cardioembolics 
(n=75; 48.1%) p
Difference NIHSS admission - 24 hours 4.17 4.08 4.27 0.900
Difference NIHSS admission - discharge 6.74 6.97 6.49 0.622
NIHSS: National Institutes of Health Stroke Scale.
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Moreover, recovery at long term, measured by mRS at 
three months, seems to be better in non-cardioembolic 
strokes. Thus, the specific role of intravenous thrombol-
ysis in different stroke subtypes still needs to be clarified 
in larger prospective trials.
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